Patents by Inventor Madeleine Antonsson

Madeleine Antonsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20220098265
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: BALAJI AGORAM, Madeleine Antonsson, MARIA A. BEDNAREK, Nicole Burmeister, Lambertus Benthem, DAVID FAIRMAN, MARIA FRITSCH-FREDIN, Ronald JACKSON, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 11230584
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20200115431
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Inventors: Balaji AGORAM, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David FAIRMAN, Maria FRITSCH-FREDIN, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 10556939
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: February 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
    Publication number: 20170342121
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 agonists for the treatment of obesity
    Patent number: 9765130
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 19, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Glucagon/GLP-1 Agonists For The Treatment Of Obesity
    Publication number: 20150307579
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 29, 2015
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe